Portfolio Sync Solutions
Streamline your investment strategy with our portfolio synchronization tools. Seamlessly manage and track your holdings across platforms for enhanced
GET STARTEDTrevi Therapeutics, Inc. Analyst EPS Estimates
| Quarter | Number of Estimates | Low Estimate | High Estimate | Average Estimate |
|---|---|---|---|---|
| Q1 2024 | 2 | -$0.11 | -$0.11 | -$0.11 |
| Q2 2024 | 2 | -$0.12 | -$0.12 | -$0.12 |
| Q3 2024 | 6 | -$0.13 | -$0.11 | -$0.12 |
| Q1 2025 | 4 | -$0.14 | -$0.11 | -$0.12 |
| Q2 2025 | 2 | -$0.12 | -$0.12 | -$0.12 |
| Q3 2025 | 2 | -$0.11 | -$0.11 | -$0.11 |
| Q4 2025 | 2 | -$0.13 | -$0.13 | -$0.13 |
| Q1 2026 | 1 | -$0.06 | -$0.06 | -$0.06 |
| Q2 2026 | 1 | -$0.06 | -$0.06 | -$0.06 |
| Q3 2026 | 1 | -$0.06 | -$0.06 | -$0.06 |
| Q4 2026 | 1 | -$0.07 | -$0.07 | -$0.07 |
| Q1 2027 | 1 | -$0.04 | -$0.04 | -$0.04 |
| Q2 2027 | 1 | -$0.04 | -$0.04 | -$0.04 |
| Q3 2027 | 1 | -$0.05 | -$0.05 | -$0.05 |
| Q4 2027 | 1 | -$0.05 | -$0.05 | -$0.05 |
| Q1 2028 | 2 | $0.30 | $0.30 | $0.30 |
| Q2 2028 | 2 | $0.30 | $0.30 | $0.30 |
| Q3 2028 | 2 | $0.30 | $0.30 | $0.30 |
| Q4 2028 | 2 | $0.32 | $0.32 | $0.32 |
Trevi Therapeutics, Inc. Earnings Date And Information
Trevi Therapeutics, Inc. last posted its earnings results on Wednesday, November 6th, 2024. The company reported $-0.13 earnings per share for the quarter, missing analysts' consensus estimates of $-0.12 by $0.01. The company had revenue of 0 for the quarter and had revenue of 0 for the year. Trevi Therapeutics, Inc. has generated $0 earnings per share over the last year ($-0.29 diluted earnings per share) and currently has a price-to-earnings ratio of -9.12. Trevi Therapeutics, Inc. has not formally confirmed its next earnings publication date, but the company's estimated earnings date is Tuesday, March 18th, 2025 based on prior year's report dates.
Trevi Therapeutics, Inc. Earnings History by Quarter
| Date | Quarter | Consensus Estimate | Reported EPS | Beat/Miss | Revenue Estimate | Actual Revenue |
|---|---|---|---|---|---|---|
| 11/06/2024 | Q3 2024 | -$0.12 | -$0.13 | -0.01 | $0 | $0 |
| 08/08/2024 | Q2 2024 | -$0.11 | -$0.12 | -0.01 | $0 | $0 |
| 05/07/2024 | Q1 2024 | -$0.09 | -$0.11 | -0.02 | $0 | |
| 03/20/2024 | Q4 2023 | -$0.10 | -$0.08 | 0.02 | $176,000 | |
| 11/09/2023 | Q3 2023 | -$0.09 | -$0.08 | 0.01 | $0 | |
| 08/10/2023 | Q2 2023 | -$0.09 | -$0.07 | 0.02 | $0 | |
| 05/11/2023 | Q1 2023 | -$0.08 | -$0.06 | 0.02 | $0 | |
| 03/16/2023 | Q4 2022 | -$0.06 | $0 | |||
| 11/10/2022 | Q3 2022 | -$0.15 | -$0.12 | 0.03 | $0 | |
| 08/11/2022 | Q2 2022 | -$0.21 | -$0.14 | 0.07 | $0 | |
| 05/12/2022 | Q1 2022 | -$0.31 | -$0.24 | 0.07 | $0 | |
| 03/17/2022 | Q4 2021 | -$0.39 | $0 | |||
| 11/10/2021 | Q3 2021 | -$0.33 | -$0.34 | -0.01 | $0 | |
| 08/12/2021 | Q2 2021 | -$0.46 | -$0.49 | -0.03 | $0 | |
| 05/13/2021 | Q1 2021 | -$0.49 | -$0.43 | 0.06 | $0 | |
| 03/25/2021 | Q4 2020 | -$0.51 | $0 | |||
| 11/12/2020 | Q3 2020 | -$0.59 | -$0.41 | 0.18 | $0 | |
| 08/13/2020 | Q2 2020 | -$0.52 | -$0.41 | 0.11 | $0 | |
| 05/07/2020 | Q1 2020 | -$0.48 | $0 | |||
| 03/16/2020 | Q4 2019 | -$0.52 | -$0.37 | 0.15 | $0 |
Trevi Therapeutics, Inc. Earnings: FAQ's
When is Trevi Therapeutics, Inc.'s earnings date?
Trevi Therapeutics, Inc. has not confirmed its next earnings publication date, but the company's estimated earnings date is Tuesday, March 18th, 2025 based off last year's report dates.
How can I listen to Trevi Therapeutics, Inc.'s earnings conference
call?
The conference call for Trevi Therapeutics, Inc.'s latest earnings report can be listened to online.
How can I read Trevi Therapeutics, Inc.'s conference call transcript?
The conference call transcript for Trevi Therapeutics, Inc.'s latest earnings report can be read online.
How much profit does Trevi Therapeutics, Inc. generate each year?
Trevi Therapeutics, Inc. (:TRVI) has a recorded net income of $0. Trevi Therapeutics, Inc. has generated $-0.29 earnings per share over the last four quarters.
What is Trevi Therapeutics, Inc.'s price-to-earnings ratio?
Trevi Therapeutics, Inc. (:TRVI) has a price-to-earnings ratio of -9.12 and price/earnings-to-growth ratio is 0.71.